Ribociclib: new antitumor drug of cyclindependent kinase 4/6 inhibitor
10.7501/j.issn.1674-6376.2017.10.032
- VernacularTitle:立博昔利布:细胞周期蛋白依赖性激酶4/6抑制剂类抗癌新药
- Author:
mei Yan WANG
1
;
Chunmiao XUE
;
wei Xiao YU
;
ling Jun CAO
Author Information
1. 北京中医药大学东直门医院药学部
- Keywords:
Ribociclib;
CDK 4/6 inhibitor;
breast cancer;
antitumor
- From:
Drug Evaluation Research
2017;40(10):1520-1524
- CountryChina
- Language:Chinese
-
Abstract:
Ribociclib is an oral small molecule cyclindependent kinase 4/6 inhibitor,which inhibits tumor progression by inhibiting the conversion of tumor cells from G1 phase to S phase.The combination ofribociclib and letrozole was approved in the United States on March 13,2017 as a treatment for HR+/HER2-advanced and metastatic breast cancer patients.Clinical results showed that the drug on advanced and metastatic tumors had a significant inhibitory effect and could extend the survival of patients without deterioration compared with using letrozole alone.The incidence of adverse drug reactions is higher,but the tolerance is better.This article focuses on pharmacodynamics,pharmacokinetic,clinical results and adverse effects of this drug.
